Supportive care in neurooncology

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 621-626

  Pace, Andrea ^a   Metro, Giulio ^a   Fabi, Alessandra ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

brain tumors; end of life; malignant gliomas; neurooncology; supportive care

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; CORTICORELIN ACETATE; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR; COTRIMOXAZOLE; DEXAMETHASONE; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; WARFARIN; XERECEPT;

BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN TUMOR; CLINICAL TRIAL; COGNITIVE DEFECT; CUSHINGOID SYNDROME; DEPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; INTERPERSONAL COMMUNICATION; LEUKOPENIA; MEDICAL DECISION MAKING; MYOPATHY; NEUROLOGY; ONCOLOGY; OPPORTUNISTIC INFECTION; PALLIATIVE THERAPY; PATIENT CARE; PATIENT EDUCATION; PNEUMOCYSTIS JIROVECI; PNEUMONIA; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; VENOUS THROMBOEMBOLISM;

BRAIN NEOPLASMS; HUMANS; PALLIATIVE CARE; TERMINAL CARE;

EID: 77958508436     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833e078c     Document Type: Review

References (44)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
2. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol 2004; 16:593-600.
3. Gomes JA, Stevens RD, Lewin JJ 3rd, et al. Glucocorticoid therapy in neurologic critical care. Crit Care Med 2005; 33:1214-1224.
4. Sur P, Sribnick E, Patel S, et al. Dexamethasone decreases temozolomide-induced apoptosis in human glioblastoma T98G cells. Glia 2005; 50:160-167.
5. Mechtler L, Wong ET, Hormigo A, et al. A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patientswith cerebral tumors. J Clin Oncol 2009; 27 (Suppl):2079. (abstract).
6. Recht LD, Mechtler L, Phuphanich S, et al. A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate inpatients with primary or metastatic brain tumors and peritumoral edema. J ClinOncol 2009; 27 (Suppl):2078. (abstract).
7. Shapiro WR, Mechtler L, Cher L, et al. A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primarymalignant glioma who require increased dexamethasone doses to controlsymptoms of peritumoral brain edema. J Clin Oncol 2009; 27 (Suppl):2080.(abstract).
8. Tjuvajev J, Uehara H, Desai R, et al. Corticotropin-releasing factor decreases vasogenic brain edema. Cancer Res 1996; 56:1352-1360.
9. Villalona-Calero MA, Eckardt J, Burris H, et al. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 1998; 9:71-77.
10. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrentglioblastoma. J Clin Oncol 2009; 27:740-745.
11. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;28:4733-4740.
12. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, inpatients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-2823.
13. Van Den Bent MJ, Vogelbaum MA, Wen PY, et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009; 27:2905-2908.
14. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, avascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survivaldespite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542-2552.
15. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89:640-646.
16. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106:601-608.
17. Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009; 115:5637-5650.
18. Perry J, Rogers L, Laperrier N, et al. PRODIGE: a phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol 2007; 25 (Suppl):2011. (abstract).
19. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300:2277-22785.
20. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 28:1527-1533.
21. Nghiemphu PL, Green RM, Pope WB, et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008; 10:355-360.
22. Bartolomeo J, Norden AD, Drappatz J, et al. Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients. J Clin Oncol 2010;(Suppl):2010. (abstract).
23. Santiago-Palma J, Payne R. Palliative care and rehabilitation. Cancer 2001;92:1049-1052.
24. Huang ME, Cifu DX, Keyser-Marcus L. Functional outcome after brain tumor and acute stroke: a comparative analysis. Arch Phys Med Rehabil 1998; 79:1386-1390.
25. Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ. Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol 2008; 7:548-560.
26. Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 2009; 27:3712-3722.
27. Pace A, Pompili A. Depression in patients with high-grade glioma: results of the Glioma project. Neurosurgery 2005; 56:E629.
28. Litofsky NS, Resnick AG. The relationships between depression and brain tumors. J Neurooncol 2009; 95:449.
29. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
30. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4):1-207.
31. Wen PY, Schiff D, Kesari S. Medical management of patients with brain tumors. J Neurooncol 2006; 80:313-332.
32. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006; 95:1155-1160.
33. Neyns B, Chaskis C, Joosens E, et al. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest 2008; 26:269-277.
34. Berrocal A, Perez Segura P, Gil M, et al. Extended-schedule dose-dense temozolomide in refractory gliomas. J Neurooncol 2010; 96:417-422.
35. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyl-transferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26:4189-4199.
36. Grossman SA, Ye X, Lesser G, et al. Iatrogenic immunosuppression in patients with high grade gliomas treated with radiation and temozolomide. J Clin Oncol 2013; 28 (Suppl). (abstract).
37. Davies E, Higginson IJ. Communication, information and support for adults with malignant cerebral glioma: a systematic literature review. Support Care Cancer 2003; 11:21-29.
38. Carver AC, Vickrey BG, Bernat JL, et al. End-of-life care. A survey of US neurologists' attitudes, behavior and knowledge. Neurology 1999; 53:284-293.
39. Triebel KL, Martin RC, Nabors LB, Marson DC. Medical decision-making capacity in patients with malignant glioma. Neurology 2009; 73:2086-2092.
40. Bosshard G, Nilstun T, Bilsen J, et al. Forgoing treatment at the end of life in 6 European countries. Arch Int Med 2005; 165:401-407.
41. Pace A, Di Lorenzo C, Guariglia L, et al. End of life issues in brain tumor patients. J Neurooncol 2009; 91:39-43.
42. Radbruch L, Nauck F, Ostgathe C, et al. What are the problems in palliative care? Results from a representative survey. Support Care Cancer 2003; 11:442-451.
43. Oberndorfer S, Lindeck-Pozza E, Lahrmann H, et al. The end-of-life hospital setting in patients with glioblastoma. J Palliat Med 2008; 11:26-30.
44. Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. Lancet Oncol 2008; 9:884-891.